Addition of Sildenafil in Patients with Pulmonary Arterial Hypertension with Inadequate Response to Bosentan Monotherapy
BACKGROUND: Pulmonary arterial hypertension (PAH) remains a progressive disease despite improvement when using one of three medication classes: prostanoids, endothelin receptor antagonists or phosphodiesterase-5 inhibitors. Combination therapy has been proposed for patients with unsatisfactory respo...
Saved in:
Main Authors: | Nancy R Porhownik, Hassan Al-Sharif, Zoheir Bshouty |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2008-01-01
|
Series: | Canadian Respiratory Journal |
Online Access: | http://dx.doi.org/10.1155/2008/897102 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Directing Therapy in Pulmonary Arterial Hypertension Using a Target 6 Min Walk Distance
by: Nancy Rose Porhownik, et al.
Published: (2013-01-01) -
Vascular Compromise and Hemodynamics in Pulmonary Arterial Hypertension: Model Predictions
by: Zoheir Bshouty
Published: (2012-01-01) -
Sildenafil Treatment of Primary Pulmonary Hypertension
by: Kevin B Laupland, et al.
Published: (2003-01-01) -
Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
by: Su-Gang Gong, et al.
Published: (2018-01-01) -
Study on the comparison between Bosentan and Macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: A randomized double-blinded non-inferiority parallel clinical trial
by: Mandana Kashaki, et al.
Published: (2025-01-01)